[go: up one dir, main page]

MX2019002962A - Inhibidores espirobiciclicos de la interaccion de menina-mll. - Google Patents

Inhibidores espirobiciclicos de la interaccion de menina-mll.

Info

Publication number
MX2019002962A
MX2019002962A MX2019002962A MX2019002962A MX2019002962A MX 2019002962 A MX2019002962 A MX 2019002962A MX 2019002962 A MX2019002962 A MX 2019002962A MX 2019002962 A MX2019002962 A MX 2019002962A MX 2019002962 A MX2019002962 A MX 2019002962A
Authority
MX
Mexico
Prior art keywords
menin
spiro bicyclic
mll interaction
inhibitors
bicyclic inhibitors
Prior art date
Application number
MX2019002962A
Other languages
English (en)
Other versions
MX392051B (es
Inventor
René Angibaud Patrick
Noëlle Constance Pilatte Isabelle
Alexis Georges Querolle Oliver
Pande Vineet
Herkert Barbara
Jason Krosky Daniel
Nathaniel Patrick Aaron
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2017/073004 external-priority patent/WO2018050686A1/en
Publication of MX2019002962A publication Critical patent/MX2019002962A/es
Publication of MX392051B publication Critical patent/MX392051B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a agentes farmaceuticos utiles para la terapia y/o profilaxis en un mamifero, y en particular a compuestos espirociclicobiciclicos, a una composicion farmaceutica que comprende dichos compuestos, y a su uso como inhibidores de la interaccion entre proteínas menina/MLL, utiles para tratar enfermedades tales como cancer, sindrome mielodisplasico (MDS) y diabetes.
MX2019002962A 2016-09-14 2017-09-13 Inhibidores espirobiciclicos de la interaccion de menina-mll MX392051B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394295P 2016-09-14 2016-09-14
EP16192431 2016-10-05
PCT/EP2017/073004 WO2018050686A1 (en) 2016-09-14 2017-09-13 Spiro bicyclic inhibitors of menin-mll interaction

Publications (2)

Publication Number Publication Date
MX2019002962A true MX2019002962A (es) 2019-07-04
MX392051B MX392051B (es) 2025-03-21

Family

ID=59895299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002962A MX392051B (es) 2016-09-14 2017-09-13 Inhibidores espirobiciclicos de la interaccion de menina-mll

Country Status (15)

Country Link
US (1) US11220517B2 (es)
EP (1) EP3512857B1 (es)
JP (1) JP6975791B2 (es)
KR (1) KR102493644B1 (es)
CN (1) CN109689663B (es)
AU (1) AU2017326487B2 (es)
BR (1) BR112019004691A2 (es)
DK (1) DK3512857T3 (es)
ES (1) ES2872003T3 (es)
HR (1) HRP20210514T1 (es)
HU (1) HUE053907T2 (es)
IL (1) IL265233B (es)
LT (1) LT3512857T (es)
MX (1) MX392051B (es)
SI (1) SI3512857T1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3033020A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
JP7142010B2 (ja) 2016-12-15 2022-09-26 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のアゼパン阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN112812584A (zh) * 2019-11-16 2021-05-18 复旦大学 一种含氮杂环丁烷螺环结构的荧光染料及其制备方法和应用
JOP20220154A1 (ar) 2019-12-19 2023-01-30 Janssen Pharmaceutica Nv مشتقات سبيرو بسلسلة مستقيمة بها استبدال
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
WO2023244870A1 (en) * 2022-06-17 2023-12-21 INSTITUTE FOR CANCER RESEARCH d.b.a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER Compositions and methods for control of transient site-specific copy gains, genomic insertions, and rearrangements associated with mixed lineage leukemia
WO2025067111A1 (zh) * 2023-09-27 2025-04-03 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
PL372145A1 (en) 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
CA2509406C (en) 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
AU2006206738A1 (en) 2005-01-19 2006-07-27 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP5343975B2 (ja) 2008-10-06 2013-11-13 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及びプログラム
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
KR20120060217A (ko) * 2009-08-20 2012-06-11 바이엘 크롭사이언스 아게 살비제 및 살충제로 사용하기 위한 3-트리아졸릴페닐-치환된 설파이드 유도체
EP2473054B1 (en) * 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
EP2590981B1 (en) * 2010-07-09 2014-09-03 Leo Pharma A/S Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
EP2620094B1 (en) 2011-08-01 2015-10-14 Olympus Corporation Apparatus for displaying shape of insertion portion
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
AU2013347538B2 (en) * 2012-11-16 2017-04-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014100730A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US9216993B2 (en) * 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US9708568B2 (en) * 2014-05-06 2017-07-18 The Procter & Gamble Company Fragrance compositions
WO2015191701A1 (en) 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CN108779116A (zh) * 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
SG11201809714TA (en) 2016-05-02 2018-11-29 Univ Michigan Regents Piperidines as menin inhibitors
WO2017207387A1 (en) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
KR20250079083A (ko) 2016-06-10 2025-06-04 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
WO2018024602A1 (en) * 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
KR102339881B1 (ko) 2016-09-06 2021-12-14 가부시끼가이샤 쓰리본드 열경화형 도전성 접착제
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
MX2019003091A (es) 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.
EA201990699A1 (ru) 2016-10-05 2019-09-30 Янссен Фармацевтика Нв Спиробициклические ингибиторы взаимодействия менин–mll
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
CN117298275A (zh) 2017-03-24 2023-12-29 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法

Also Published As

Publication number Publication date
US11220517B2 (en) 2022-01-11
HUE053907T2 (hu) 2021-07-28
AU2017326487A1 (en) 2019-02-28
IL265233A (en) 2019-05-30
EP3512857A1 (en) 2019-07-24
SI3512857T1 (sl) 2021-07-30
KR102493644B1 (ko) 2023-01-30
AU2017326487B2 (en) 2021-08-05
JP2019532100A (ja) 2019-11-07
BR112019004691A2 (pt) 2019-06-25
JP6975791B2 (ja) 2021-12-01
IL265233B (en) 2021-06-30
KR20190045242A (ko) 2019-05-02
HRP20210514T1 (hr) 2021-05-14
MX392051B (es) 2025-03-21
CN109689663A (zh) 2019-04-26
EP3512857B1 (en) 2021-02-24
LT3512857T (lt) 2021-04-12
ES2872003T3 (es) 2021-11-02
US20190211036A1 (en) 2019-07-11
CN109689663B (zh) 2023-04-14
DK3512857T3 (da) 2021-05-10

Similar Documents

Publication Publication Date Title
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2022001583A1 (es) Derivados espiráncos sustituidos de cadena lineal
BR112018012707A2 (pt) inibidores da interação de menin-mll
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CL2015002386A1 (es) Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo.
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
MX2016011036A (es) Compuestos de éter para el tratamiento de trastornos mediados por complemento.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
UY35602A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2017000142A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.
MX2023013176A (es) Derivados espiro sustituidos.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma